Fineline Cube

Follow:
14486 Articles
NHSA Completes 2025 Drug Negotiation Review; CAR‑T Therapies Clear the Hurdle
Policy / Regulatory

NHSA Completes 2025 Drug Negotiation Review; CAR‑T Therapies Clear the Hurdle

Shenzhen Salubris Submits NMPA NDA for SAL003, a Once‑Monthly Anti‑PCSK9 Biologic
CompanyDrug

Shenzhen Salubris Submits NMPA NDA for SAL003, a Once‑Monthly Anti‑PCSK9 Biologic

Biogen Acquires Alcyone Therapeutics to Drive ThecaFlex DRx Implant Development
CompanyDeals

Biogen Acquires Alcyone Therapeutics to Drive ThecaFlex DRx Implant Development

Henlius Organon Secure EU Marketing Approval for BILDYOS and BILPREVDA Denosumab Biosimilars
CompanyDrug

Henlius Organon Secure EU Marketing Approval for BILDYOS and BILPREVDA Denosumab Biosimilars

Innovent Secures 2nd NMPA Approval for Mazdutide – First Dual GLP‑1/GCGR Therapy for Type 2 Diabetes
CompanyDrug

Innovent Secures 2nd NMPA Approval for Mazdutide – First Dual GLP‑1/GCGR Therapy for Type 2 Diabetes

AusperBio Secures $63 Million Series B2 Financing to Propel AHB‑137 Development
CompanyDeals

AusperBio Secures $63 Million Series B2 Financing to Propel AHB‑137 Development

Pfizer and Arvinas Pass Commercial Rights of Vepdegestrant to Third Party
CompanyDeals

Pfizer and Arvinas Pass Commercial Rights of Vepdegestrant to Third Party

Guangdong Taienkang Secures NMPA Approval for Safinamide Generic
CompanyDrug

Guangdong Taienkang Secures NMPA Approval for Safinamide Generic

Hengrui Pharma Secures Breakthrough Therapy Designation for SHR‑1501 in China
CompanyDrug

Hengrui Pharma Secures Breakthrough Therapy Designation for SHR‑1501 in China

GE Healthcare Eyes Sale of China Unit Amid Revenue Decline
Others

GE Healthcare Eyes Sale of China Unit Amid Revenue Decline

Hengrui Pharma Secures NMPA Approval for Two Novel Immune‑Inflammatory Drugs
CompanyDrug

Hengrui Pharma Secures NMPA Approval for Two Novel Immune‑Inflammatory Drugs

GenSci Secures Exclusive Rights to ALK’s House Dust Mite Allergy Therapies in China
CompanyDeals

GenSci Secures Exclusive Rights to ALK’s House Dust Mite Allergy Therapies in China